MNI China Daily Summary: Monday, July 29

MNI: China CFETS Yuan Index Up 0.15% In Week of Jul 26

MNI: PBOC Net Injects CNY243.37 Bln via OMO Monday

MNI: PBOC Sets Yuan Parity Higher At 7.1316 Mon; -1.56% Y/Y

CHINA PBOC CONDUCTS CNY301.57 BILLION VIA 7-DAY REVERSE REPOS MON

CHINA SETS YUAN CENTRAL PARITY AT 7.1316 MON VS 7.1270

CBI Retail Sales Fell Faster Than Expected For The Second Month

MNI: UK CBI JUL DIST TRADE REPORTED SALES -43

MNI: UK BOE JUN MORTGAGE APPROVALS 59,976

RPT-MNI: Canada Sticks To Fiscal Anchors, Spends Chunk Of Windfall

© 1982-2024 MNI. All rights reserved.
Terms | Privacy
Log Out
Free Trial

Mixed Reac To AstraZeneca Vaccine News

MNI

After the overnight report that AstraZeneca / Oxford's COVID vaccine trial had been paused as one of the participants was diagnosed with an unexplained illness, there have been a couple of reports of note this afternoon (and interestingly, AZN's share price is up on the day after early sharp losses).

  • Earlier this afternoon, the FT reported citing sources that the trials could resume as soon as next week. And later in the afternoon, Statnews' Adam Feuerstein Tweeted: "The Covid19 vaccine trial participant had serious neurological symptoms, but could be discharged today, AstraZeneca CEO says…Pascal Soriot held a private conference call with investors, spilled new information."
  • Overall, the market impact has been fairly muted in both directions on these headlines, suggesting either a lack of concern over the latest trial setback, and/or expectations that if the AZN vaccine doesn't pan out, there are plenty of contenders that might.
Energy BulletsCommodities
Energy BulletsCommodities

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.